Abiopharma

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

(70% Positive) Biofrontera Inc. (BFRI) Announces Business Combination

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Silo Pharma Notification (SILO)

Biofrontera Notification (BFRI)

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Financial Statements and Related Announcement: Third Quarter Results

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

Spectral AI raises $7.6 Million of Additional Growth Capital

Intelligent Bio Solutions Inc. - Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider

ICU Medical Announces Time of Third Quarter 2025 Earnings Conference Call